NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD
PRELUDE THERAPEUTICS INC
NASDAQ:PRLD (2/10/2025, 8:18:45 PM)
After market: 0.9 -0.19 (-17.43%)1.09
+0.08 (+7.92%)
The current stock price of PRLD is 1.09 USD. In the past month the price increased by 2.83%. In the past year, price decreased by -76.46%.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy •...
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.81 | 336.36B | ||
AMGN | AMGEN INC | 14.87 | 158.46B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1620.59 | 121.03B | ||
GILD | GILEAD SCIENCES INC | 21.55 | 118.99B | ||
REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.86B | ||
ARGX | ARGENX SE - ADR | N/A | 38.66B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.35B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.63B | ||
ONC | BEIGENE LTD-ADR | N/A | 23.41B | ||
NTRA | NATERA INC | N/A | 22.73B | ||
BIIB | BIOGEN INC | 8.73 | 20.77B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.18 | 15.43B |
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 128 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
PRELUDE THERAPEUTICS INC
175 Innovation Boulevard
Wilmington DELAWARE 19803 US
CEO: Krishna Vaddi
Employees: 128
Company Website: https://preludetx.com/
Investor Relations: https://investors.preludetx.com/
Phone: 13024671280
The current stock price of PRLD is 1.09 USD.
The exchange symbol of PRELUDE THERAPEUTICS INC is PRLD and it is listed on the Nasdaq exchange.
PRLD stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PRLD, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PRLD.
PRLD does not pay a dividend.
PRLD will report earnings on 2025-02-13, after the market close.
PRLD does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
The outstanding short interest for PRLD is 11.41% of its float.
ChartMill assigns a technical rating of 2 / 10 to PRLD. When comparing the yearly performance of all stocks, PRLD is a bad performer in the overall market: 93.09% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PRLD. While PRLD has a great health rating, there are worries on its profitability.
Over the last trailing twelve months PRLD reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 18.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -66.69% | ||
ROE | -84.07% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 76% to PRLD. The Buy consensus is the average rating of analysts ratings from 11 analysts.